Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Dotinurad

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Crystalys Therapeutics Names Thacker CFO for Dotinurad Phase 3
    Crystalys Therapeutics Names Thacker CFO for Dotinurad Phase 3

    21 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/crystalys-therapeutics-expands-leadership-team-with-appointment-of-justin-thacker-as-chief-financial-officer-to-support-advancement-of-phase-3-trials-of-dotinurad-302665997.html

    PR NEWSWIRE
    21 Jan 2026
    Share Share
    Crystalys Therapeutics Progresses Dotinurad Phase 3 Trials
    Crystalys Therapeutics Progresses Dotinurad Phase 3 Trials

    21 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/crystalys-therapeutics-advances-phase-3-trials-of-dotinurad-for-the-treatment-of-gout-with-dosing-of-first-patients-302589382.html

    PR NEWSWIRE
    21 Oct 2025
    Share Share
    Fortress, Urica Dose First Patients In Ph3 Dotinurad Gout Trial
    Fortress, Urica Dose First Patients In Ph3 Dotinurad Gout Trial

    21 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/21/3170212/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-First-Patients-Dosed-in-Crystalys-Therapeutics-Global-Phase-3-Trials-of-Dotinurad-for-the-Treatment-of-Gout.html

    GLOBENEWSWIRE
    21 Oct 2025
    Share Share
    Fortress Biotech And Urica Therapeutics Unveil Crystalys
    Fortress Biotech And Urica Therapeutics Unveil Crystalys

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/01/3159491/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-Crystalys-Therapeutics-205-Million-Series-A-Financing.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    Fezolinetant and Dotinurad WC Certificate
    Fezolinetant and Dotinurad WC Certificate

    16 Sep 2025

    // PRESS RELEASE

    https://www.loncompharm.com/Fezolinetant-and-Dotinurad-WC-Certificate-id48151685.html

    PRESS RELEASE
    16 Sep 2025
    Share Share
    Revarazan Hcl For Acute Gastritis, Chronic Gastritis Gastric Mucosal Lesions
    Revarazan Hcl For Acute Gastritis, Chronic Gastritis Gastric Mucosal Lesions

    28 Mar 2024

    // PRESS RELEASE

    https://www.tantuchemicals.com/news/revarazan-hcl-for-acute-gastritis-chronic-gas-76202020.html

    PRESS RELEASE
    28 Mar 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.